Keeping you up to date on recent developments in neurology, including: New smart drug delivery system may help treatment for neurological disorders; Imaging probe developed for Alzheimer's disease; Potential target identified for migraine therapy.
In August, Cala Health Inc. reported results from its pivotal PROSPECT study showing significant improvement in hand tremors with use of its Cala Trio wearable neuromodulation therapy. Now the company has real-world evidence affirming the benefit to patients with essential tremor (ET) who used Cala Trio at home over several months.
TORONTO – Most doctors recognize the symptoms instantly: hand tremors, slurred speech, impaired posture and balance. What they don’t always associate with people suffering from Parkinson’s disease are hallucinations and delusions.
Click Therapeutics Inc. and Boehringer Ingelheim GmbH inked a deal valued at more than $500 million to collaborate on the development and commercialization of a prescription-based digital therapeutic for schizophrenia. The mobile application, currently called CT-155, uses cognitive and neurobehavioral techniques to reduce the symptoms of schizophrenia, such as cognitive deficits and impaired social functioning.
Keeping you up to date on recent developments in neurology, including: New molecule restores lost connections in the spinal cord, brain of mice; Brain stimulation reduces dyslexia deficits; Nerivio wearable piloted for relief in patients with chronic migraine.
RapidAI, which focuses on imaging for stroke, has launched the Rapid Web App to help stroke teams stay updated on imaging results and communicate securely. Using the app, team members can receive real-time browser notifications of new cases, preview Rapid results and source files and engage in workflow communications via a desktop or laptop computer.
Minnetronix Medical Inc. has won the U.S. FDA’s nod for its Mindseye Expandable Port for neurosurgical procedures. The company touts the device as the first minimally invasive, retractable deep brain access system for use in the treatment of stroke, cancer and other conditions.
Keeping you up to date on recent developments in neurology, including: Sleep quality linked to onset; progression of Alzheimer's; Using magnetic resonance elastography to detect epilepsy; How can hearing loss cause dementia?
Neuropace Inc. has scooped up $67 million in a financing round that was led by Accelmed Partners. The funds will be used to accelerate commercial growth of its brain-responsive neurostimulator (RNS), as well as to advance new indications for the U.S. FDA-cleared system.
The FDA came through at last for Athlone, Ireland-based Innocoll Holdings Ltd., greenlighting the drug-device combo Xaracoll (bupivacaine HCl) for acute postsurgical pain relief for up to 24 hours in adults after open inguinal hernia repair.
RSS
